A chronic acquired immune-mediated neuropathy characterized by progressive or relapsing-remitting symmetric proximal and distal weakness with sensory involvement. Distinguished from GBS by duration greater than 8 weeks and chronic course.
CIDP is an immune-mediated disorder of peripheral nerves characterized by heterogeneous, overlapping mechanisms that variably involve cellular immunity (T cells, macrophages), humoral autoimmunity (B cells, autoantibodies), complement activation, and disruption of the blood–nerve barrier (BNB). Pathology classically shows macrophage-mediated segmental demyelination, with inflammatory infiltrates of T cells and macrophages within endoneurium; humoral mechanisms are supported by immunoglobulin deposition and, in defined subgroups, pathogenic autoantibodies against nodal/paranodal proteins that disrupt axo–glial junctions without prominent inflammation. Complement activation (including terminal C5b-9 deposition) appears to promote demyelination and correlates with inflammatory cell infiltration and severity in biopsy cohorts. Therapeutic responsiveness to IVIg, corticosteroids, and plasma exchange underscores antibody and immune effector contributions, while newer strategies—FcRn blockade and complement inhibition—further link specific pathways to disease activity. Overall, CIDP encompasses at least two mechanistic archetypes: (1) macrophage/complement-driven segmental demyelination; and (2) nodal/paranodal autoantibody-mediated “autoimmune nodopathies,” now defined as distinct from classical CIDP, with unique treatment implications. (vallat2024pathologyexplainsvarious pages 8-8, caballeroavila2025apathophysiologicaland pages 1-2, caballeroavila2025apathophysiologicaland pages 5-6, caballeroavila2025apathophysiologicaland pages 2-3)
| Mechanism/Process | Key molecules (HGNC) | Cell types (CL) | Cellular components (GO-CC) | Biological processes (GO-BP) | Evidence & year (PMID/DOI, URL) |
|---|---|---|---|---|---|
| Macrophage-mediated segmental demyelination | Fc gamma receptors (FCGRs, e.g., FCGR3A); myelin proteins (e.g., MPZ, PMP22) | Macrophage (CL: macrophage), Schwann cell (CL: Schwann cell) | Myelin sheath (GO:0043209); endoneurium | Macrophage-mediated phagocytosis of myelin; segmental demyelination | (vallat2024pathologyexplainsvarious pages 8-8) Vallat & Mathis 2024; DOI: 10.1111/bpa.13184; https://doi.org/10.1111/bpa.13184 |
| T- and B-cell involvement (adaptive immunity) | CD4 (CD4), CD8A (CD8A), CD20 (MS4A1), BAFF (TNFSF13B) | CD4+ T cell, CD8+ T cell, B cell / plasma cell | Immune synapse / lymphocyte plasma membrane (GO-CC) | Antigen processing and presentation; T-cell cytotoxicity; B-cell antibody production | (kmezic2025biomarkerandpathogenic pages 150-152, kmezic2025biomarkerandpathogenic pages 178-181) Kmezic 2025; DOI: 10.69622/28457924.v1; https://doi.org/10.69622/28457924.v1 |
| Nodal/paranodal autoantibodies (autoimmune nodopathy) | NFASC (isoforms NF155, NF186/140), CNTN1, CNTNAP1 (CASPR1) | Schwann cell (paranodal glia), axonal paranode | Node of Ranvier (GO:0033268); paranodal junction (GO-CC) | Disruption of node/paranode assembly, loss of ion-channel clustering, conduction block | (vallat2024pathologyexplainsvarious pages 8-8, appeltshauser2024casereporttarget pages 8-8) Vallat 2024; Appeltshauser 2024 (case report) DOI: 10.1111/bpa.13184, 10.3389/fimmu.2024.1475478 |
| Complement activation (terminal pathway / MAC) | Complement components C3, C5, membrane attack complex (C5b-9) | Macrophages, endoneurial endothelial cells, Schwann cells | Membrane attack complex (GO:0030442); endoneurial capillary | Complement activation, opsonization, MAC-mediated membrane injury and promotion of demyelination | (caballeroavila2025apathophysiologicaland pages 5-6, vallat2024pathologyexplainsvarious pages 8-8) Caballero-Ávila 2025 DOI: 10.3389/fimmu.2025.1575464; Vallat 2024 DOI: 10.1111/bpa.13184 |
| Blood–nerve barrier (BNB) disruption / increased permeability | Tight junction proteins (e.g., CLDN5), chemokines (e.g., CCLs) | Peripheral nerve microvascular endothelial cell (CL), pericyte | Blood–nerve barrier / tight junction (GO-CC) | Increased vascular permeability, leukocyte extravasation into endoneurium | (kmezic2025biomarkerandpathogenic pages 178-181, kmezic2025biomarkerandpathogenic pages 29-35) Kmezic 2025 DOI: 10.69622/28457924.v1; (supporting BNB findings in related studies) |
| Fluid/serologic biomarkers (diagnostic/prognostic) | NEFL (NfL), IL8 (IL-8), PTGDS (beta-trace protein) | Neurons/axons (NEFL), immune cells (IL8), CSF-producing cells (PTGDS) | Neuronal cytoskeleton (GO:0043227); extracellular region/CSF (GO:0005576) | Axonal injury release (NfL); chemokine signaling (IL-8); CSF protein changes reflecting barrier dysfunction (beta-trace) | (kmezic2025biomarkerandpathogenic pages 150-152, kmezic2025biomarkerandpathogenic pages 178-181) Kmezic 2025 DOI: 10.69622/28457924.v1 (NfL, IL-8, beta-trace validated in cohorts) |
| Therapeutic mechanisms (mechanism-linked interventions) | IVIg (polyclonal IgG), FCGRT (FcRn target for efgartigimod), MS4A1 (CD20; rituximab), C5 / C1s (eculizumab / anti-complement agents) | B cells / plasma cells (targeted by rituximab), FcR-expressing macrophages, endothelial cells | Extracellular region; endosomal FcRn recycling compartment (GO-CC) | IgG neutralization and Fc modulation (IVIg); immunosuppression (corticosteroids); antibody removal (PLEX); B-cell depletion (rituximab); IgG lowering via FcRn blockade (efgartigimod); complement blockade (anti-C5/anti-C1s) | (caballeroavila2025apathophysiologicaland pages 5-6, kmezic2025biomarkerandpathogenic pages 178-181, appeltshauser2024casereporttarget pages 8-8) Caballero-Ávila 2025 DOI: 10.3389/fimmu.2025.1575464; Kmezic 2025 DOI: 10.69622/28457924.v1; Appeltshauser 2024 DOI: 10.3389/fimmu.2024.1475478 |
Table: Compact summary linking major CIDP mechanisms to molecules, cell types, cellular locations (GO-CC), processes (GO-BP) and recent evidence (context IDs, DOIs/URLs). Useful for ontology annotation and knowledge-base entry drafting.
Limitations and open questions: Several mechanistic details remain unresolved in seronegative CIDP; the extent and clinical utility of complement profiling and antibody discovery beyond established nodal/paranodal targets require larger studies; biomarker cutoffs and implementation pathways continue to evolve.
References
(vallat2024pathologyexplainsvarious pages 8-8): Jean‐Michel Vallat and Stéphane Mathis. Pathology explains various mechanisms of auto‐immune inflammatory peripheral neuropathies. Brain Pathology, Jun 2024. URL: https://doi.org/10.1111/bpa.13184, doi:10.1111/bpa.13184. This article has 22 citations and is from a domain leading peer-reviewed journal.
(caballeroavila2025apathophysiologicaland pages 1-2): Marta Caballero-Ávila, Lorena Martin-Aguilar, Roger Collet-Vidiella, Luis Querol, and Elba Pascual-Goñi. A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy. Frontiers in Immunology, Apr 2025. URL: https://doi.org/10.3389/fimmu.2025.1575464, doi:10.3389/fimmu.2025.1575464. This article has 6 citations and is from a peer-reviewed journal.
(caballeroavila2025apathophysiologicaland pages 5-6): Marta Caballero-Ávila, Lorena Martin-Aguilar, Roger Collet-Vidiella, Luis Querol, and Elba Pascual-Goñi. A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy. Frontiers in Immunology, Apr 2025. URL: https://doi.org/10.3389/fimmu.2025.1575464, doi:10.3389/fimmu.2025.1575464. This article has 6 citations and is from a peer-reviewed journal.
(caballeroavila2025apathophysiologicaland pages 2-3): Marta Caballero-Ávila, Lorena Martin-Aguilar, Roger Collet-Vidiella, Luis Querol, and Elba Pascual-Goñi. A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy. Frontiers in Immunology, Apr 2025. URL: https://doi.org/10.3389/fimmu.2025.1575464, doi:10.3389/fimmu.2025.1575464. This article has 6 citations and is from a peer-reviewed journal.
(kmezic2025biomarkerandpathogenic pages 150-152): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.
(kmezic2025biomarkerandpathogenic pages 178-181): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.
(appeltshauser2024casereporttarget pages 8-8): Luise Appeltshauser, Helena Glenewinkel, Sophia Rohrbacher, Lena Wessely, Carmen Villmann, Claudia Sommer, and Kathrin Doppler. Case report: target antigen and subclass switch in a patient with autoimmune nodopathy. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1475478, doi:10.3389/fimmu.2024.1475478. This article has 4 citations and is from a peer-reviewed journal.
(kmezic2025biomarkerandpathogenic pages 29-35): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.
(kmezic2025biomarkerandpathogenic pages 44-47): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.
name: Chronic Inflammatory Demyelinating Polyneuropathy
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-02-17T21:53:14Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Peripheral Neuropathy
disease_term:
preferred_term: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
term:
id: MONDO:0006702
label: chronic inflammatory demyelinating polyradiculoneuropathy
description: >-
A chronic acquired immune-mediated neuropathy characterized by progressive
or relapsing-remitting symmetric proximal and distal weakness with sensory
involvement. Distinguished from GBS by duration greater than 8 weeks and
chronic course.
pathophysiology:
- name: T Cell-Mediated Demyelination
description: >-
CD4+ and CD8+ T cells infiltrate peripheral nerves and contribute to
demyelination. T cells recognize myelin antigens and produce inflammatory
cytokines that damage Schwann cells.
cell_types:
- preferred_term: CD4+ T Cell
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
- preferred_term: CD8+ T Cell
term:
id: CL:0000625
label: CD8-positive, alpha-beta T cell
biological_processes:
- preferred_term: Adaptive Immune Response
term:
id: GO:0002250
label: adaptive immune response
evidence:
- reference: PMID:37356965
reference_title: "Pathology explains various mechanisms of auto-immune inflammatory peripheral neuropathies."
supports: PARTIAL
snippet: >-
Autoimmune neuropathies are a heterogeneous group of rare and disabling diseases
in which the immune system is thought to target antigens in the peripheral
nervous system: they usually respond to immune therapies.
explanation: >-
This pathology review confirms that CIDP involves immune-mediated targeting
of peripheral nerve antigens, supporting the role of adaptive immunity including
T cell responses in disease pathogenesis.
- name: Antibody and Complement-Mediated Damage
description: >-
Autoantibodies against myelin proteins and nodal/paranodal antigens
(neurofascin, contactin-1) contribute to demyelination. Complement
deposition amplifies nerve damage.
biological_processes:
- preferred_term: Complement Activation
term:
id: GO:0006956
label: complement activation
- preferred_term: Immunoglobulin Production
term:
id: GO:0002377
label: immunoglobulin production
evidence:
- reference: PMID:35378684
reference_title: "The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies."
supports: SUPPORT
snippet: >-
The complement system appears to play a role in promoting macrophage-mediated
demyelination.
explanation: >-
This review establishes the role of complement activation in CIDP pathogenesis,
linking complement to the amplification of macrophage-mediated nerve damage.
- reference: PMID:36346134
reference_title: "Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage."
supports: SUPPORT
snippet: >-
Besides IgG4, subclass IgG3 was detected and associated with complement binding
and cytotoxic effects in vitro.
explanation: >-
Experimental evidence showing that IgG3 subclass antibodies activate complement,
demonstrating complement-mediated pathogenic mechanisms in autoantibody-positive
CIDP.
- name: Macrophage-Mediated Myelin Stripping
description: >-
Activated macrophages invade nerve fibers and actively strip myelin from
axons, causing segmental demyelination visible on nerve biopsy.
cell_types:
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
biological_processes:
- preferred_term: Inflammatory Response
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:37356965
reference_title: "Pathology explains various mechanisms of auto-immune inflammatory peripheral neuropathies."
supports: PARTIAL
snippet: >-
In contrast, the mechanisms of demyelination of other dysimmune neuropathies
induced by macrophages are unexplained, as no antibodies have been identified
in such cases.
explanation: >-
This pathology review acknowledges macrophage-induced demyelination as a distinct
mechanism in CIDP, occurring even in cases without identified autoantibodies,
supporting the role of innate immune responses independent of antibody-mediated
damage.
- reference: PMID:36645654
reference_title: "Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations."
supports: PARTIAL
snippet: >-
The proposed mechanisms of action of IVIg that can mediate its therapeutic effects
are reviewed. These include anti-idiotypic interactions, inhibition of neonatal
Fc
receptors (FcRn), anti-complement activity, upregulation of inhibitory FcγRIIB
receptors, and downregulation of macrophage activation.
explanation: >-
IVIg therapy works in part by downregulating macrophage activation, providing
indirect
evidence that macrophages play a central pathogenic role in CIDP that can be
therapeutically
targeted.
phenotypes:
- name: Progressive Weakness
category: Neurological
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Limb Muscle Weakness
term:
id: HP:0003690
label: Limb muscle weakness
notes: Symmetric, proximal and distal
- name: Areflexia
category: Neurological
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Areflexia
term:
id: HP:0001284
label: Areflexia
- name: Sensory Loss
category: Neurological
frequency: FREQUENT
phenotype_term:
preferred_term: Peripheral Sensory Neuropathy
term:
id: HP:0000763
label: Sensory neuropathy
evidence:
- reference: PMID:38330421
reference_title: "Sensory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Neglected Immunotherapy-Responsive Sensory Neuropathy."
supports: SUPPORT
snippet: >-
Sensory CIDP was diagnosed when two inclusion criteria are met: 1) acquired,
chronic progressive or relapsing symmetrical or asymmetrical sensory polyneuropathy
that had progressed for >2 months.
explanation: >-
This clinical study establishes sensory polyneuropathy as a diagnostic criterion
and key phenotype of sensory CIDP variant, demonstrating that sensory loss is
a
prominent and treatable feature in CIDP.
- name: Fatigue
category: Systemic
frequency: FREQUENT
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
biochemical:
- name: CSF Protein
presence: Elevated
context: Without pleocytosis
- name: Anti-Neurofascin Antibodies
presence: Variable
context: Associated with specific CIDP subtype
- name: Anti-Contactin-1 Antibodies
presence: Variable
context: Associated with specific CIDP subtype
treatments:
- name: IVIG
description: First-line therapy for most patients.
- name: Corticosteroids
description: Alternative first-line therapy.
- name: Plasmapheresis
description: For refractory cases or acute exacerbations.
- name: Rituximab
description: For antibody-positive refractory cases.
classifications:
harrisons_chapter:
- classification_value: nervous system disorder
- classification_value: neuromuscular disease
- classification_value: autoimmune disease
references:
- reference: DOI:10.1111/bpa.13184
title: Pathology explains various mechanisms of auto‐immune inflammatory
peripheral neuropathies
findings: []
- reference: DOI:10.3389/fimmu.2024.1475478
title: 'Case report: target antigen and subclass switch in a patient with autoimmune
nodopathy'
findings: []
- reference: DOI:10.3389/fimmu.2025.1575464
title: A pathophysiological and mechanistic review of chronic inflammatory
demyelinating polyradiculoneuropathy therapy
findings: []
- reference: DOI:10.69622/28457924.v1
title: Biomarker and pathogenic study of immune-mediated neuropathies
findings: []